Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Berberine on Hormonal and Metabolic Features in Obese Women With PCOS
Brief Summary: Berberine has showed effective in lowering blood sugar levels in db/db mice and anti-dyslipidemia in human.Studies on the effect of berberine on metabolic and hormonal features of women with polycystic ovary syndrome (PCOS) are lacking.The objective of this study is to examine the effect of Berberine metabolic and hormonal parameters and insulin resistance in obese patients with PCOS.


Options:
A: Inclusion Criteria:

* Female partner age 21 up to 40th birthday, at the time of recruitment. Infertility is defined as failure to conceive a recognized pregnancy after one year (or 12 menstrual cycles) of unprotected intercourse.
* Male partner has a normal semen analysis with a sperm concentration of \>15 million total motile sperm, \>1% normal forms by strict criteria, or \>5 million total motile sperm on IUI prep.
* Female patient has at least one ovary and at least one ipsilateral patent fallopian tube confirmed by HSG or laparoscopy; pelvic pathology amenable to operative laparoscopy (pelvis restored to functional). The open tube cannot have had a previous ectopic (tubal) pregnancy and the closed tube cannot be a hydrosalpinx (a tube that is blocked at the end and filled with fluid), unless a tubal ligation has been performed at the junction of the uterus and fallopian tube.
* Patients with surgically corrected stages I and II endometriosis will be included.
* Normal uterine cavity demonstrated by HSG, Sonohysterogram (SHG), or hysteroscopy; pathologies of uterine cavity amenable to operative hysteroscopy (cavity restored to normal and demonstrated by post operative study).
* Anovulatory patients who did not conceive after a minimum of three ovulatory cycles with any medications, not including gonadotropin therapy. Anovulatory patients unable to achieve ovulation at dosages up to 150 mg of clomiphene or standard dosages of other ovulation inducing medications (i.e. bromocriptine). Hypoestrogenic hypothalamic amenorrhea patients will qualify immediately for inclusion, prior to any gonadotropin therapy.
* Normal ovarian reserve demonstrated in all patients i.e., cycle day 3 FSH/E2 values of \<15 mIU/mL and \<100 pg/mL, respectively. Normal TSH and prolactin.
* Female body mass index ≤ 38.

Exclusion Criteria:

* Previous tubal reconstructive surgery in which the pelvis was not restored to functional.
* Unilateral or bilateral hydrosalpinx (a tube that is blocked at the end and filled with fluid) that has not had a tubal ligation performed at the junction of the uterus and fallopian tubes.
* A laparoscopy that demonstrated pelvic adhesions or endometriosis for which the pelvis could not be restored to normal by surgery or endometriosis was not ablated or excised. All patients with stages III and IV endometriosis.
* One or more prior ectopic pregnancies in which one or both tubes were rendered nonfunctional; two or more ectopic pregnancies, even if tubes are patent.
* Severe male factor (i.e.; semen analysis with a sperm concentration of \<15 million total motile sperm, \<1% normal forms by strict criteria, or \<5 million total motile sperm on IUI prep). Couples using donor semen will be excluded.
* Previous treatment with IUI or IVF. Previous treatment of normal ovulation patients with gonadotropins.
* Inadequate ovarian reserve demonstrating FSH \>15 mIU/mL or estradiol \> 100 pg/mL.
* Patients requiring gamete intrafallopian tube transfer (GIFT), zygote intrafallopian tube transfer (ZIFT), or tubal embryo transfer (TET).
* Female body mass index \> 38.
B: Inclusion Criteria:

* Infertile patients having early endometriosis as the only factor of their infertility

Exclusion Criteria:

* Previous treatment for endometriosis or patients having pelvic disorders in addition to endometriosis
C: Inclusion Criteria:

* Diagnosis of PCOS based on the revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS (2003).
* All women were previously treated with 100 mg of CC daily for 5 days per cycle, for two to three cycles with persistent anovulation or ovulate with very thin endometrium \<5 mm at the time of hCG administration

Exclusion Criteria:

* patients with hyperprolactinaemia,
* hypercorticism and
* thyroid dysfunction.
* patients receiving medications as cholesterol lowering drugs, as statins, beta-blockers, and tricyclic antidepressants
D: Inclusion Criteria

1. Age of women between 18 and 35 years.
2. Confirmed diagnosis of PCOS according to the modified Rotterdam criteria and all subjects must have anovulation plus either polycystic ovaries and/or hyperandrogenism.
3. Body mass index (BMI) equal to or greater than 23 kg/m2.
4. With no desire of children within 6 month. PCOS is defined by the modified Rotterdam criteria: oligomenorrhea or amenorrhea, together with presence of ≥12 antral follicles (≤9mm) and/or ovarian volume \>10 ml on transvaginal scanning, and/or clinical/biochemical hyperandrogenism. Oligomenorrhea is defined as an intermenstrual interval \>35 days and \<8 menstrual bleedings in the past year. Amenorrhea is defined as an intermenstrual interval \>90 days. Clinical hyperandrogenism in China Mainland is defined as a Ferriman-Gallwey (FG) score ≥5.

Exclusion criteria are

1. Use of hormonal drugs or other medications including Chinese Herbal prescriptions in the past 3 months.
2. Patients with other endocrine disorders including 21-hydroxylase deficiency, hyperprolactinemia, uncorrected thyroid disease, suspected Cushing's syndrome
3. Patients with known sever organ dysfunction or mental illness.

Answer: D